Summary
IDEXX Laboratories, Inc. reported solid financial results for the first quarter of 2011, demonstrating revenue growth driven by its core Companion Animal Group (CAG) segment. Total revenue increased by 9.0% to $292.7 million, with organic revenue growth of 7.8%. The CAG segment, which represents the largest portion of revenue, saw an 8.7% increase in revenue, primarily fueled by strong performance in instruments, consumables, and reference laboratory services. The company also showed improvements in profitability, with net income attributable to IDEXX stockholders rising to $36.6 million, a 10.8% increase from the prior year's quarter.
Financial Highlights
50 data pointsBeta
Financial Statements
Beta
| Revenue | $292.67M |
| Cost of Revenue | $137.75M |
| Gross Profit | $154.93M |
| R&D Expenses | $17.81M |
| Operating Income | $53.53M |
| Interest Expense | $728K |
| Net Income | $36.61M |
| EPS (Basic) | $0.32 |
| EPS (Diluted) | $0.31 |
| Shares Outstanding (Basic) | 114.91M |
| Shares Outstanding (Diluted) | 118.18M |
Key Highlights
- 1Total revenue for the first quarter of 2011 was $292.7 million, an increase of 9.0% compared to the same period in 2010.
- 2Organic revenue growth, excluding the impact of currency fluctuations and acquisitions, was 7.8%.
- 3The Companion Animal Group (CAG) segment remains the largest revenue driver, with a 8.7% increase in revenue.
- 4Net income attributable to IDEXX stockholders was $36.6 million, up 10.8% from Q1 2010.
- 5Diluted Earnings Per Share (EPS) increased to $0.62 from $0.55 in the prior year's quarter.
- 6The company maintained a strong balance sheet with $153.5 million in cash and cash equivalents and $192.9 million in working capital at the end of the quarter.
- 7Cash flow from operating activities increased to $25.2 million, reflecting improved net income and operational efficiency.
Frequently Asked Questions
Revenue growth was primarily driven by the Companion Animal Group (CAG) segment, with increases in instruments and consumables sales, and strong performance in reference laboratory diagnostic and consulting services. The Livestock and Poultry Diagnostics (LPD) segment also saw significant growth.
Overall operating expenses increased by 7.9% to $101.4 million. However, revenue growth outpaced expense growth, leading to an 10.5% increase in operating income to $53.5 million. Profitability was further supported by a slight decrease in the effective income tax rate and robust net income growth.
Management indicated that while economic conditions have affected demand, particularly in the CAG and Water segments, the company's diverse product offerings and geographic reach are expected to mitigate some of the negative impacts. They anticipate continued pressure from slow economic growth and cautious consumer sentiment but remain focused on executing their strategies for growth.
The company disclosed ongoing investigations by the U.S. Federal Trade Commission (FTC) and the UK Office of Fair Trading (OFT) concerning marketing and sales practices for companion animal veterinary products and services. While the company believes its practices are compliant, the duration and outcome of these investigations are unpredictable.